Unlocking CSU pathogenesis to shape the future treatment landscape episode artwork

EPISODE · Apr 11, 2022 · 38 MIN

Unlocking CSU pathogenesis to shape the future treatment landscape

from touchPODCAST · host touchpodcast

touchPANEL DISCUSSION for touchIMMUNOLOGY Listen to a panel of experts discuss how emerging endotypes in chronic spontaneous urticaria are driving the development of much-needed new treatment and management approaches. The experts: Prof. Dr med. Marcus Maurer – Charité University Medicine, Berlin, Germany Dr Melinda Gooderham – SKiN Centre for Dermatology, Ontario, Canada Prof. David Khan – Southwestern Medical Center, University of Texas, USA This touchPODCAST is for HCPs only.  This activity is funded by an unrestricted independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchimmunologyime.org/csu-pathogenesis-to-treatment/ 

Episode metadata supplied by the publisher feed · Published Apr 11, 2022

Embed this episode

Ready to play

Unlocking CSU pathogenesis to shape the future treatment landscape

0:00 38:22

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 38 minutes long.

When was this touchPODCAST episode published?

This episode was published on April 11, 2022.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!